Your browser is no longer supported. Please, upgrade your browser.
CBLI Cleveland BioLabs, Inc. monthly Stock Chart
CBLI [NASD]
Cleveland BioLabs, Inc.
Index- P/E- EPS (ttm)-0.19 Insider Own56.41% Shs Outstand13.00M Perf Week15.51%
Market Cap44.49M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float5.67M Perf Month42.28%
Income-2.10M PEG- EPS next Q- Inst Own6.70% Short Float7.87% Perf Quarter86.17%
Sales0.90M P/S49.43 EPS this Y26.70% Inst Trans-7.50% Short Ratio0.17 Perf Half Y98.86%
Book/sh-0.17 P/B- EPS next Y- ROA-86.00% Target Price2.00 Perf Year299.58%
Cash/sh0.24 P/C14.83 EPS next 5Y- ROE76.10% 52W Range0.51 - 5.43 Perf YTD481.40%
Dividend- P/FCF- EPS past 5Y-19.00% ROI52.50% 52W High-35.54% Beta0.68
Dividend %- Quick Ratio6.70 Sales past 5Y-21.40% Gross Margin- 52W Low579.61% ATR0.32
Employees7 Current Ratio6.70 Sales Q/Q-83.80% Oper. Margin- RSI (14)66.12 Volatility8.28% 9.00%
OptionableNo Debt/Eq- EPS Q/Q-44.00% Profit Margin- Rel Volume0.07 Prev Close3.11
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume2.55M Price3.50
Recom- SMA2014.14% SMA5036.22% SMA20056.50% Volume175,920 Change12.54%
Jan-24-14Downgrade Oppenheimer Outperform → Perform
Mar-21-13Initiated Cantor Fitzgerald Buy $4
Dec-06-12Initiated Oppenheimer Outperform $3
Dec-04-12Initiated Burrill Institutional Research Mkt Outperform $4
Feb-02-11Initiated Wedbush Outperform $10
Oct-13-10Downgrade WBB Securities Strong Buy → Hold $6.50 → $6.50
Sep-17-10Reiterated Rodman & Renshaw Mkt Outperform $8 → $11
Jul-21-10Downgrade WBB Securities Strong Buy → Speculative Buy $6.50
Sep-29-09Initiated Rodman & Renshaw Mkt Outperform $8
Nov-24-20 03:50PM  
Nov-23-20 08:31PM  
Nov-20-20 09:28PM  
Nov-13-20 06:59PM  
12:27PM  
Nov-12-20 01:31PM  
Nov-11-20 03:18PM  
Nov-10-20 06:00AM  
Nov-07-20 02:40PM  
Nov-06-20 10:16PM  
09:43AM  
09:18AM  
Nov-04-20 05:13PM  
10:55AM  
Nov-03-20 05:46PM  
01:16PM  
Oct-31-20 07:15PM  
Oct-29-20 07:40PM  
10:30AM  
Oct-27-20 05:05PM  
01:53PM  
10:15AM  
Oct-26-20 03:33PM  
02:52PM  
02:45PM  
01:42PM  
Oct-24-20 02:10PM  
Oct-23-20 04:45PM  
Oct-22-20 05:45PM  
Oct-21-20 10:20PM  
08:54PM  
02:33PM  
12:52PM  
10:45AM  
10:10AM  
08:30AM  
08:04AM  
Oct-20-20 06:51PM  
06:21PM  
01:44PM  
10:50AM  
08:30AM  
08:17AM  
Oct-19-20 04:05PM  
Jun-03-20 04:05PM  
Jun-01-20 08:30AM  
May-15-20 09:00AM  
Jan-28-20 07:53AM  
07:12AM  
Nov-18-19 06:58AM  
Nov-14-19 04:30PM  
Oct-04-19 10:25AM  
Aug-20-19 01:40PM  
Aug-14-19 08:30AM  
Jun-12-19 10:30AM  
May-25-19 08:15AM  
May-15-19 08:30AM  
Mar-07-19 08:15AM  
Feb-07-19 11:58AM  
Dec-14-18 02:22PM  
Dec-06-18 09:31AM  
Nov-23-18 07:20AM  
Nov-14-18 07:30AM  
Oct-05-18 01:24PM  
Aug-14-18 05:15PM  
04:45PM  
Aug-06-18 05:00PM  
Jun-22-18 03:12PM  
Jun-12-18 07:30AM  
May-31-18 04:18PM  
May-15-18 08:00AM  
Apr-17-18 02:37PM  
Mar-28-18 05:05PM  
Mar-06-18 08:00AM  
Feb-21-18 04:28PM  
Feb-09-18 02:02PM  
Jan-01-18 02:45PM  
Dec-29-17 11:40AM  
Dec-22-17 04:55PM  
Dec-13-17 12:55PM  
Dec-01-17 07:00AM  
Nov-30-17 01:36PM  
Nov-29-17 08:17AM  
Nov-22-17 08:40PM  
Nov-15-17 11:38AM  
Nov-14-17 08:15AM  
Nov-08-17 04:49PM  
Oct-26-17 10:23AM  
Oct-11-17 11:17AM  
Sep-19-17 05:11PM  
Sep-18-17 12:02PM  
Sep-11-17 03:57PM  
Aug-11-17 08:00AM  
Aug-04-17 07:26PM  
Jul-12-17 02:18PM  
Jun-26-17 03:32PM  
Jun-16-17 03:31PM  
Jun-05-17 02:06PM  
Jun-02-17 10:27AM  
May-15-17 07:30AM  
Cleveland BioLabs, Inc., a biopharmaceutical company, develops novel approaches to activate the immune system and address various medical needs in the United States and Russia. Its proprietary platform of toll-like immune receptor activators (TLR) has applications in mitigation of radiation injury, radiation oncology, and vaccines. The company's product candidate is entolimod, an immune-stimulatory agent, which is used as a medical radiation countermeasure and other indications in radiation oncology. It is also developing Mobilan, a recombinant non-replicating adenovirus that directs expression of TLR5 and its agonistic ligand. Cleveland BioLabs, Inc. has strategic partnerships with the Cleveland Clinic, Roswell Park Cancer Institute, and Everon Biosciences. The company was founded in 2003 and is headquartered in Buffalo, New York.
affiliate | advertise | contact | privacy | help
Do not sell my personal information

Quotes delayed 15 minutes for NASDAQ, and 20 minutes for NYSE and AMEX.
Copyright © 2007-2020 FINVIZ.com. All Rights Reserved.